Tenaya Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on the stock and has a $3.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors related to Tenaya Therapeutics’ ongoing research and development efforts. The company is set to present significant data from its Phase 1b/2 MyPEAK-1 study, which investigates the effects of AAV9-TN-201 on MYBPC3-HCM, a condition with a substantial unmet medical need. The early data from the low-dose cohort indicated promising signs of target engagement, with increases in MYBPC3 mRNA and improvements in biomarkers and functional endpoints, despite some challenges in interpreting protein expression changes due to biopsy limitations.
Jubinville remains optimistic about the potential therapeutic benefits of TN-201, particularly with the upcoming high-dose cohort data, which could provide clearer insights into protein expression and dose-response relationships. The observed stabilization and improvements in structural and functional endpoints, such as LVMI and NYHA class, suggest a meaningful impact of TN-201 on patients. These developments, coupled with the anticipation of more definitive data from the high-dose cohort, underpin the Buy rating, as they point towards the potential for broader dosing and therapeutic impact in the future.
Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Larimar Therapeutics, and Rocket Pharmaceuticals. According to TipRanks, Jubinville, PhD has an average return of 17.4% and a 54.13% success rate on recommended stocks.